Melo de Paula A J
Clin Ther. 1984;6(4):500-8.
Lormetazepam (1 and 2 mg) was tested against flurazepam (30 mg) and placebo in 60 patients (15 per treatment group) with initial, intermediate, or late insomnia. Patients were randomly assigned to treatment groups, and a double-blind protocol was followed. The four-week study included one week of use of the placebo, followed by two weeks of treatment with the active drug (in three groups) or continued use of the placebo (one group), and one week of use of the placebo (all four groups). Results showed that the active drugs were efficient in controlling insomnia. In some subjective parameters, only 2 mg of lormetazepam was significantly better than placebo. Tolerability of the drugs was considered good, with no interruption of treatment required because of adverse reactions. There was a rebound effect in one patient receiving 1 mg of lormetazepam and in three patients receiving flurazepam.
在60名患有初发性、中度或晚期失眠的患者（每个治疗组15名）中，对氯美扎酮（1毫克和2毫克）与氟西泮（30毫克）及安慰剂进行了测试。患者被随机分配到各治疗组，并遵循双盲方案。为期四周的研究包括一周安慰剂使用期，随后两周使用活性药物治疗（三个组）或继续使用安慰剂（一组），以及一周安慰剂使用期（所有四个组）。结果表明，活性药物在控制失眠方面有效。在一些主观参数上，仅2毫克氯美扎酮显著优于安慰剂。药物耐受性良好，未因不良反应而中断治疗。在一名接受1毫克氯美扎酮的患者和三名接受氟西泮的患者中出现了反跳效应。
